386 related articles for article (PubMed ID: 12558910)
1. Early viral kinetics on treatment with pegylated interferon-alpha-2a in chronic hepatitis C virus genotype 1 infection.
Jessner W; Stauber R; Hackl F; Datz C; Watkins-Riedel T; Hofer H; Gangl A; Kessler H; Ferenci P
J Viral Hepat; 2003 Jan; 10(1):37-42. PubMed ID: 12558910
[TBL] [Abstract][Full Text] [Related]
2. Neutralizing antibodies to interferon-α and circulating interferon in patients with chronic hepatitis C non-responding to pegylated interferon plus ribavirin re-treated by pegylated interferon-α-2a and ribavirin (ANRS HC16 GAMMATRI substudy).
Halfon P; Pérusat S; Bourlière M; Bronowicki JP; Trimoulet P; Benhamou Y; Leroy V; Marcellin P; Foucher J; Penaranda G; Chêne G; Couzigou P;
J Med Virol; 2010 Dec; 82(12):2027-31. PubMed ID: 20981789
[TBL] [Abstract][Full Text] [Related]
3. Pegylated alpha-interferon-2a plus ribavirin compared with pegylated alpha-interferon-2b plus ribavirin for initial treatment of chronic hepatitis C virus: prospective, non-randomized study.
Escudero A; Rodríguez F; Serra MA; Del Olmo JA; Montes F; Rodrigo JM
J Gastroenterol Hepatol; 2008 Jun; 23(6):861-6. PubMed ID: 18422960
[TBL] [Abstract][Full Text] [Related]
4. Enhanced efficacy of pegylated interferon alpha-2a over pegylated interferon and ribavirin in chronic hepatitis C genotype 4A randomized trial and quality of life analysis.
Kamal SM; Ahmed A; Mahmoud S; Nabegh L; El Gohary I; Obadan I; Hafez T; Ghoraba D; Aziz AA; Metaoei M
Liver Int; 2011 Mar; 31(3):401-11. PubMed ID: 21281434
[TBL] [Abstract][Full Text] [Related]
5. Pegylated interferon alpha-2a and -2b in combination with ribavirin in the treatment of chronic hepatitis C: a systematic review and economic evaluation.
Shepherd J; Brodin H; Cave C; Waugh N; Price A; Gabbay J
Health Technol Assess; 2004 Oct; 8(39):iii-iv, 1-125. PubMed ID: 15461877
[TBL] [Abstract][Full Text] [Related]
6. Lead-in treatment with interferon-β/ribavirin may modify the early hepatitis C virus dynamics in pegylated interferon alpha-2b/ribavirin combination for chronic hepatitis C patients with the IL28B minor genotype.
Itokawa N; Atsukawa M; Tsubota A; Kondo C; Hashimoto S; Fukuda T; Matsushita Y; Kidokoro H; Kobayashi T; Narahara Y; Nakatsuka K; Kanazawa H; Iwakiri K; Sakamoto C
J Gastroenterol Hepatol; 2013 Mar; 28(3):443-9. PubMed ID: 23173698
[TBL] [Abstract][Full Text] [Related]
7. Early and sustained virological response in non-responders with chronic hepatitis C: a randomized open-label study of pegylated interferon-alpha-2a versus pegylated interferon-alpha-2b.
Scotto G; Fazio V; Fornabaio C; Tartaglia A; Di Tullio R; Saracino A; Angarano G
Drugs; 2008; 68(6):791-801. PubMed ID: 18416586
[TBL] [Abstract][Full Text] [Related]
8. [Efficacy and safety of pegylated interferon α-2b injection (Y shape, 40 kD) in treatment of patients with genotype 1/6 chronic hepatitis C].
Feng B; Shang J; Wu SH; Chen H; Han Y; Li YQ; Zhang DZ; Zhao LF; Wei SF; Mao Q; Yin CB; Han T; Wang MR; Chen SJ; Li J; Xie Q; Zhen Z; Gao ZL; Zhang YX; Gong GZ; Yang DL; Pan C; Sheng JF; Tang H; Ning Q; Shi GF; Niu JQ; Luo GH; Sun YT; You H; Wang GQ; Zhang LL; Peng J; Zhang Q; Liu JJ; Chen CW; Chen XY; Zhao W; Wang RH; Sun L; Wei L
Zhonghua Gan Zang Bing Za Zhi; 2017 Mar; 25(3):187-194. PubMed ID: 28482405
[No Abstract] [Full Text] [Related]
9. Very early viral kinetics on interferon treatment in chronic hepatitis C virus genotype 4 infection.
Jessner W; Gschwantler M; Formann E; Gurguta C; Watkins-Riedel T; Wrba F; Ferenci P
Antivir Ther; 2008; 13(4):581-9. PubMed ID: 18672537
[TBL] [Abstract][Full Text] [Related]
10. Peginterferon alpha-2a (40 KD) plus ribavirin for the treatment of chronic hepatitis C in Japanese patients.
Kuboki M; Iino S; Okuno T; Omata M; Kiyosawa K; Kumada H; Hayashi N; Sakai T
J Gastroenterol Hepatol; 2007 May; 22(5):645-52. PubMed ID: 17444850
[TBL] [Abstract][Full Text] [Related]
11. Baseline anti-NS4a antibodies in combination with on-treatment quantitative HCV-RNA reliably identifies nonresponders to pegylated interferon-ribavirin combination therapy after 4 weeks of treatment.
Orlent H; Desombere I; Hansen B; Van Vlierberghe H; Haagmans B; De Knegt RJ; Schalm SW; Leroux-Roels G; Janssen HL;
Eur J Gastroenterol Hepatol; 2010 Dec; 22(12):1443-8. PubMed ID: 21389795
[TBL] [Abstract][Full Text] [Related]
12. Predictive value of rapid virological response and early virological response on sustained virological response in HCV patients treated with pegylated interferon alpha-2a and ribavirin.
Yu JW; Wang GQ; Sun LJ; Li XG; Li SC
J Gastroenterol Hepatol; 2007 Jun; 22(6):832-6. PubMed ID: 17565637
[TBL] [Abstract][Full Text] [Related]
13. Response to pegylated interferon alfa-2a and ribavirin in chronic hepatitis C genotype 4.
El Makhzangy H; Esmat G; Said M; Elraziky M; Shouman S; Refai R; Rekacewicz C; Gad RR; Vignier N; Abdel-Hamid M; Zalata K; Bedossa P; Pol S; Fontanet A; Mohamed MK
J Med Virol; 2009 Sep; 81(9):1576-83. PubMed ID: 19626613
[TBL] [Abstract][Full Text] [Related]
14. Early viral kinetics and treatment outcome in combination of high-dose interferon induction vs. pegylated interferon plus ribavirin for naive patients infected with hepatitis C virus of genotype 1b and high viral load.
Tsubota A; Arase Y; Someya T; Suzuki Y; Suzuki F; Saitoh S; Ikeda K; Akuta N; Hosaka T; Kobayashi M; Kumada H
J Med Virol; 2005 Jan; 75(1):27-34. PubMed ID: 15543591
[TBL] [Abstract][Full Text] [Related]
15. Peginterferon alpha-2a and ribavirin versus peginterferon alpha-2a monotherapy in early virological responders and peginterferon alpha-2a and ribavirin versus peginterferon alpha-2a, ribavirin and amantadine triple therapy in early virological nonresponders: the SMIEC II trial in naïve patients with chronic hepatitis C.
Angelico M; Koehler-Horst B; Piccolo P; Angelico F; Gentile S; Francioso S; Tarquini P; Vecchia RD; Ponti L; Pilleri G; Barlattani A; Grieco A; Soccorsi F; Guarascio P; Demelia L; Sorbello O; Rossi Z; Forlini G; Zaru S; Bandiera F;
Eur J Gastroenterol Hepatol; 2008 Jul; 20(7):680-7. PubMed ID: 18679072
[TBL] [Abstract][Full Text] [Related]
16. Long-term pegylated interferon monotherapy following 72 weeks of pegylated interferon and ribavirin in hepatitis C virus genotype-1-infected slow responders.
Watanabe S; Kobayashi Y; Kawata K; Noritake H; Chida T; Nagasawa M; Kageyama F; Kawamura K; Sasada Y; Suda T
Intern Med; 2015; 54(3):273-9. PubMed ID: 25748735
[TBL] [Abstract][Full Text] [Related]
17. Predictive value of early virological response to treatment with different interferon-based regimens plus ribavirin in patients with chronic hepatitis C.
Napoli N; Giannelli G; Parisi CV; Antonaci A; Maddalena G; Antonaci S
New Microbiol; 2005 Jan; 28(1):13-21. PubMed ID: 15782622
[TBL] [Abstract][Full Text] [Related]
18. Viral kinetic of HCV genotype-4 during pegylated interferon alpha 2a: ribavirin therapy.
Derbala MF; El Dweik NZ; Al Kaabi SR; Al-Marri AD; Pasic F; Bener AB; Shebl FM; Amer AM; Butt MT; Yakoob R; John A; Al Mohanadi M; Al Khinji MA
J Viral Hepat; 2008 Aug; 15(8):591-9. PubMed ID: 18482284
[TBL] [Abstract][Full Text] [Related]
19. Pegylated interferon alpha 2b and ribavirin in HIV/hepatitis C virus-co-infected non-responders and relapsers to IFN-based therapy.
Myers RP; Benhamou Y; Bochet M; Thibault V; Mehri D; Poynard T
AIDS; 2004 Jan; 18(1):75-9. PubMed ID: 15090832
[TBL] [Abstract][Full Text] [Related]
20. Efficacy of double filtration plasmapheresis with pegylated interferon/ribavirin therapy for intractable chronic hepatitis C patients and hepatitis C patients with combined liver cirrhosis by HBV, leading to early viral elimination.
Ohara T; Oteki T; Suzuki T; Suzuki M; Matsuzaki Y
Hepatogastroenterology; 2011; 58(105):133-6. PubMed ID: 21510300
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
